Regulation of TCR-induced IFN-γ release from islet-reactive non-obese diabetic CD8+ T cells by prostaglandin E2 receptor signaling

被引:36
作者
Ganapathy, V [1 ]
Gurlo, T [1 ]
Jarstadmarken, HO [1 ]
von Grafenstein, H [1 ]
机构
[1] Univ So Calif, Sch Pharm, Los Angeles, CA 90033 USA
关键词
cell-cell interactions; cytokine; cytotoxic T lymphocyte; diabetes; rodent;
D O I
10.1093/intimm/12.6.851
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Prostaglandins (PG) are released during tissue injury and inflammation, and inhibit immune responses at many points. PG may be one of several factors that protect not only against injury-induced, but also spontaneous, organ-specific autoimmune disease. Here we show that the production of PGE(2), normally produced at a very low rate in islets of Langerhans, is significantly increased in inflamed islets of non-obese diabetic (NOD) mice, We investigated a possible role of PGE(2) in controlling TCR-dependent release of IFN-gamma from islet-reactive NOD CD8(+) T cells. PGE(2) inhibited anti-TCR antibody-triggered release of IFN-gamma from CD8(+) T cell clone 8D8 and from polyclonal cytotoxic T lymphocytes (CTL), Using receptor subtype selective agonists, we present evidence that the effect of PGE(2) is mediated by EP2 and EP4 receptors, both of which are coupled to an increase In intracellular cAMP production. The cAMP analogs 8-Br-cAMP and Sp-cAMPS mimic the effect of EP2/EP4 receptor agonists, inhibiting TCR-triggered IFN-gamma release from NOD CD8(+) T cells in a dose-dependent manner. The inhibitory effect of PGE(2) was largely reversed by IL-2 added at the time of culture initiation and decreased with increasing strength of stimulation through the TCR, Resting CTL were more sensitive to PGE, than recently expanded CTL and NOD CD8(+) T cells remained insensitive to PGE(2) for a longer time than BALB/c cells. Our study suggests that PGE(2) may be part of a regulatory network that controls local activation of T cells and may play a role in the balance between the development of islet autoimmunity or maintenance of tolerance.
引用
收藏
页码:851 / 860
页数:10
相关论文
共 64 条
  • [1] RESISTANCE OF ESTABLISHED ISLET ALLOGRAFTS TO REJECTION BY ANTIBODY AND COMPLEMENT
    AGOSTINO, M
    PROWSE, SJ
    LAFFERTY, KJ
    [J]. AUSTRALIAN JOURNAL OF EXPERIMENTAL BIOLOGY AND MEDICAL SCIENCE, 1982, 60 (APR): : 219 - 222
  • [2] Checkpoints in the progression of autoimmune disease: Lessons from diabetes models
    Andre, I
    Gonzalez, A
    Wang, B
    Katz, J
    Benoist, C
    Mathis, D
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (06) : 2260 - 2263
  • [3] ATKINSON MA, 1994, NEW ENGL J MED, V331, P1428
  • [4] Autoimmune diabetes: how many steps for one disease?
    Bach, JF
    Chatenoud, L
    Herbelin, A
    Gombert, JM
    Carnaud, C
    [J]. RESEARCH IN IMMUNOLOGY, 1997, 148 (05): : 332 - 338
  • [5] The NOD mouse - Introduction
    Bach, JF
    Mathis, D
    [J]. RESEARCH IN IMMUNOLOGY, 1997, 148 (05): : 285 - 286
  • [6] BETZ M, 1991, J IMMUNOL, V146, P108
  • [7] Prostaglandin E2 enhancement of interferon-γ production by antigen-stimulated type 1 helper T cells
    Bloom, D
    Jabrane-Ferrat, N
    Zeng, L
    Wu, A
    Lo, D
    Turck, CW
    An, S
    Goetzl, EJ
    [J]. CELLULAR IMMUNOLOGY, 1999, 194 (01) : 21 - 27
  • [8] Identification of a calcium-inducible, cyclosporine-sensitive element in the IFN-gamma promoter that is a potential NFAT binding site
    Campbell, PM
    Pimm, J
    Ramassar, V
    Halloran, PF
    [J]. TRANSPLANTATION, 1996, 61 (06) : 933 - 939
  • [9] Caruso A, 1998, EUR J IMMUNOL, V28, P3630, DOI 10.1002/(SICI)1521-4141(199811)28:11<3630::AID-IMMU3630>3.0.CO
  • [10] 2-6